ZURICH, June 10, 2026, 10:45 CEST
Roche Holding Ltd. participation certificates listed on SIX traded up 1.07% at CHF 322.20 late Wednesday morning. Investors were eyeing a new $2.3 billion deal with Nurix Therapeutics, bringing Roche a late-stage blood-cancer asset. The stock line now trades as ROP after the company switched from the former ROG Genussscheine in March. Roche’s bearer shares are listed as RO.
The Swiss Market Index edged higher, gaining roughly 0.35% to 13,403.50. The SMI tracks Switzerland’s top 20 blue chips by size and liquidity, recalculating in real time as stocks change hands.
Roche’s exclusive licensing and collaboration deal with Nurix for bexobrutideg, or NX-5948, is driving the move. Bexobrutideg is a BTK degrader, not a blocker, targeting Bruton’s tyrosine kinase—a key protein that controls B-cell growth. Roche said it plans to start Phase 3 trials this summer in second-line chronic lymphocytic leukemia, or CLL. The late-stage testing aims to confirm the drug’s safety and effectiveness before any regulatory submission.
Nurix is getting $700 million upfront from Roche, but milestone payments could bring the deal’s total to $2.3 billion. Roche is picking up 60% of development costs and Nurix will pay 40%. The companies will share U.S. profits and losses 50-50. Roche takes commercial rights outside the U.S., with Nurix set to get royalties.
Investors are watching because Roche is buying into a drug that’s already nearing key trials, rather than an early-stage project. Roche said clinical data so far indicate bexobrutideg might bring improved efficacy and tolerability over current therapies, and could address resistance seen with BTK inhibitors. Nurix said they plan to expand into multiple sclerosis and chronic spontaneous urticaria, moving into Phase 2 studies.
Roche Chief Medical Officer Levi Garraway said the drug bexobrutideg “could represent a major leap forward” for treating tough blood cancers. Roche called the commercial potential significant. The company said BTK-targeting assets are within the non-Hodgkin lymphoma and CLL markets, which it expects will hit $41 billion by 2031. Roche
Roche’s push to add new growth drivers comes as it swaps out older cancer drugs hit by biosimilar rivals and patent loss. For 2025, the company said its five fastest-growing medicines brought in CHF 3.2 billion more at constant exchange rates, though drugs with expired patents dropped by CHF 0.7 billion. Roche expects mid-single-digit sales growth and high-single-digit core EPS growth in 2026, using its adjusted earnings measure.
Timing is part of the story. Reuters reported that Roche Deputy Chief Medical Officer Stefan Frings said bexobrutideg might launch around 2030 if Phase 3 results go well. That sets a rough timeline for when the Nurix asset could start generating revenue instead of just being a pipeline drug, but late-stage oncology trials can always miss.
Roche said it’s sticking with a €600 million outlay for a new diagnostics site in Penzberg, Germany, Reuters reported. This comes after Eli Lilly cut its planned $2.3 billion investment in Germany by half, and Boehringer Ingelheim canceled €900 million in projects. Roche plans to review future spending in the country, with Roche Pharma AG CEO Daniel Steiners saying a cabinet move is “creating a new degree of uncertainty.” Reuters
There’s a risk the Nurix deal brings expectations before earnings. Bexobrutideg is still in testing, with late-stage trials that might not meet targets and potential for new side effects. The partnership also needs to clear antitrust checks and other deal requirements. Nurix highlights in its SEC filing that splitting U.S. commercialization is complicated and delays could hit regulatory or clinical timelines.
Investors are already eyeing two upcoming dates: Roche and Nurix say the deal should wrap up in Q3 2026, while Roche is set to kick off Phase 3 testing in CLL this summer. How those events play out could decide if Wednesday’s pipeline hopes stick.
